Publisher: Informa Healthcare
ISSN: 1354-3776
Source: Expert Opinion on Therapeutic Patents, Vol.7, Iss.1, 1997-01, pp. : 79-80
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
These patents disclose a series of diphenylpyridines and diphenylisoxazoles which are reported to be potent and selective cyclooxygenase-2 (COX-2) inhibitors. Among the best derivatives claimed, only compounds in the diphenylisoxazole series exhibit an in vivo biological profile comparable to indomethacin in an inflammatory and analgesia model. Consequently, these inhibitors are of great interest in terms of their in vivo pharmacology, either for use as anti-inflammatory agents or for the treatment of pain with reduced ulcerogenic side-effects.
Related content
Potent and selective cyclooxygenase-2 inhibitors
Expert Opinion on Therapeutic Patents, Vol. 7, Iss. 3, 1997-03 ,pp. :
Selective inhibitors of cyclooxygenase-2
By Talley J.J.
Expert Opinion on Therapeutic Patents, Vol. 7, Iss. 1, 1997-01 ,pp. :
Arylpyridazinones as selective cyclooxygenase-2 inhibitors
Expert Opinion on Therapeutic Patents, Vol. 9, Iss. 12, 1999-12 ,pp. :